CHARRIKA KELLY: Open Payments
NPI 1114517935 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,044 in 101 payments from 16 companies in 2025. Trend: 2023 $42 · 2024 $845 · 2025 $2,044
Food & beverage: $2,044
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $696 |
| PFIZER INC. | 16 | $268 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $231 |
| Ardelyx, Inc. | 6 | $149 |
| Gilead Sciences, Inc. | 5 | $148 |
| GENZYME CORPORATION | 4 | $104 |
| Madrigal Pharmaceuticals | 4 | $91 |
| Janssen Biotech, Inc. | 3 | $71 |
| Celltrion USA Inc. | 4 | $61 |
| QOL Medical, LLC | 3 | $60 |
Products named: LINZESS, SKYRIZI, XIFAXAN, VELSIPITY, IBSRELA, DUPIXENT, CREON, XELJANZ.
Industry payments across MD — which companies pay providers there.
